High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

By Connie StonePosted on

Whereas target-specific medication can be found for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailor-made remedy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary […]

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Read More